Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism

Drugs of Today

Volumn 42, Issue 1, 2006, Pages 39-64

  Fruchart, Jean Charles ^a,b   Duriez, Patrick ^a  

^a UNIV LILLE   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN C3; BEZAFIBRATE; CIPROFIBRATE; CLOFIBRIC ACID DERIVATIVE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLITAZONE DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; MEGALIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIRINIXIC ACID; SCAVENGER RECEPTOR BI; TRIACYLGLYCEROL;

BILE SECRETION; CHOLESTEROL ESTERIFICATION; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; DRUG MECHANISM; DYSLIPOPROTEINEMIA; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN HYDROLYSIS; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; BEZAFIBRATE; BIOLOGICAL TRANSPORT; CHOLESTEROL, HDL; CLOFIBRIC ACID; CORONARY ARTERIOSCLEROSIS; GEMFIBROZIL; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIVER; PPAR ALPHA; PROCETOFEN; RANDOMIZED CONTROLLED TRIALS; TRIGLYCERIDES;

EID: 33645076793     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2006.42.1.963528     Document Type: Review

References (136)

1. Kannel, W.B., Castelli, W.P., Gordon, T., McNamara, P.M. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med 1971, 74: 1-12.
2. Stamler, J., Wentworth, D., Neaton, J.D. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986, 256: 2823-8.
3. Smith, G.D., Shipley, M.J., Marmot, M.G., Rose, G. Plasma cholesterol concentration and mortality. The Whitehall Study. JAMA 1992, 267: 70-6.
4. Gordon, D.J., Probstfield, J.L., Garrison, R.J. et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989, 79: 8-15.
5. Wilson, P.W., Abbott, R.D., Castelli, W.P. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988, 8: 737-41.
6. Assmann, G., Schulte, H., von Eckardstein, A., Huang, Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996, 124(Suppl.): S11-S20.
7. Gordon, D.J., Rifkind, B.M. High-density lipoprotein-the clinical implications of recent studies. N Engl J Med 1989, 321: 1311-6.
8. Rubins, H.B., Robins, S.J., Collins, D. et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999, 341: 410-8.
9. Schaefer, E.J., Gregg, R.E., Ghiselli, G. et al. Familial apolipoprotein E deficiency. J Clin Invest 1986, 78: 1206-19.
10. Austin, M.A. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991, 11: 2-14.
11. Hodis, H.N., Mack, W.J., Azen, SP. et al. Triglyceride-and cholesterol-rich lipoproteine have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994, 90: 42-9.
12. Assmann, G., Schulte, H. Role of triglycerides in coronary artery disease: Lessons from the Prospective Cardiovascular Munster Study. Am J Cardiol 1992, 70: 10H-13H.
13. Manninen, V., Tenkanen, L., Koskinen, P. et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992, 85: 37-45.
14. Hokanson, J.E., Austin, M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996, 3: 213-9.
15. Askanas, Z., Malanowicz, W., Zambrowicz, K. Effect of Atromid on plasma lipids and fibrinolysis in patients with a history of myocardial infarct. Pol Arch Med Wewn 1965, 35: 5-11.
16. Orsetti, A., Mirouze, J. Effect of ethyl α-p- chlorophenoxyisobutyrate (clofibrate) on lipids, cholesterol and uric acid in diabetes mellitus. Therapie 1966, 21: 685-91.
17. Prevention of coronary heart disease: Scientific background and new clinical guidelines: Recommendations of the European Atherosclerosis Society prepared by International Task Force for Prevention of Coronary Heart Disease. Nutr Metab Cardiovasc Dis 1992, 2: 113-56.
18. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993, 269: 3015-23.
19. Issemann, I., Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990, 347: 645-50.
20. Gonzalez, F.J., Peters, J.M., Cattley, R.C. Mechanism of action of the nongenotoxic peroxisome proliferators: Role of the peroxisome proliferator-activator receptor α. J Natl Cancer Inst 1998, 90: 1702-9.
21. Vanden Heuvel, J.P. Peroxisome proliferator-activated receptors: A critical link among fatty acids, gene expression and carcinogenesis. J Nutr 1999, 129: 575-80.
22. Schoonjans, K., Peinado-Onsurbe, J., Lefebvre, A.M. et al. PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 1996, 15: 5336-48.
23. Vu-Dac, N., Gervois, P., Jakel, H. Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor α activators. J Biol Chem 2003, 278: 17982-5.
24. Prieur, X., Coste, H., Rodriguez, J.C. The human apolipoprotein AV gene is regulated by PPARα and contains a novel FXR response element. J Biol Chem 2003, 278: 25468-80.
25. Staels, B., Vu-Dac, N., Kosykh, V.A. et al. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 1995, 95: 705-12.
26. Malmendier, C.L., Delcroix, C. Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia. Atherosclerosis 1985, 55: 161-9.
27. Vu-Dac, N., Schoonjans, K., Laine, B., Fruchart, J.C., Auwerx, J., Staels, B. Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem 1994, 269: 31012-8.
28. Vu-Dac, N., Schoonjans, K., Kosykh, V. et al. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 1995, 96: 741-50.
29. Ericsson, C.G., Nilsson, J., Grip, L., Svane, B., Hamsten, A. Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]). Am J Cardiol 1997, 80: 1125-9.
30. Ruotolo, G., Ericsson, C.G., Tettamanti, C. et al. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol 1998, 32: 1648-56.
31. Goldbourt, U., Brunner, D., Behar, S., Reicher-Reiss, H. Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study. Eur Heart J 1998, 19(Suppl. H): H42-7: H42-H47.
32. Ericsson, C.G., Hamsten, A., Nilsson, J., Grip, L., Svane, B., de Faire, U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996, 347: 849-53.
33. Seconday prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study. Circulation 2000, 102: 21-7.
34. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001, 357: 905-10.
35. Syvanne, M., Nieminen, M.S., Frick, M.H. et al. Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol. Circulation 1998, 98: 1993-9.
36. Boden, W.E. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: Assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol 2000, 86: 19-22.
37. Miller, M. Differentiating the effects of raising low levels of high-density lipoprotein cholesterol versus lowering normal triglycerides: Further insights from the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol 2000, 86: 23L-27L.
38. Schoonjans, K., Staels, B., Auwerx, J. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996, 1302: 93-109.
39. Martin, G., Schoonjans, K., Lefebvre, A.M., Staels, B., Auwerx, J. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARα and PRARγ activators. J Biol Chem 1997, 272: 28210-7.
40. Motojima, K., Passilly, P., Peters, J.M., Gonzalez, F.J., Latruffe, N. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor α and γ activators in a tissue- and inducer-specific manner. J Biol Chem 1998, 273: 16710-4.
41. Mascaro, C., Acosta, E., Ortiz, J.A., Marrero, P.F., Hegardt, F.G., Haro, D. Control of human muscle-type carnitine palmitoyltransferase I gene transcription by peroxisome proliferator-activated receptor. J Biol Chem 1998, 273: 8560-3.
42. Brandt, J.M., Djouadi, F., Kelly, D.P. Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor α. J Biol Chem 1998, 273: 23786-92.
43. Djouadi, P., Weinheimer, C.J., Saffitz, J.E. et al. A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor α-deficient mice. J Clin Invest 1998, 102: 1083-91.
44. Meertens, L.M., Miyata, K.S., Cechetto, J.D., Rachubinski, R.A., Capone, J.P. A mitochondrial ketogenic enzyme regulates its gene expression by association with the nuclear hormone receptor PPARα. EMBO J 1998, 17: 6972-8.
45. Kelly, L.J., Vicario, P.P., Thompson, G.M. Peroxisome proliferator-activated receptors-γ and α mediate in vivo regulation of uncoupling protein (UCP-1, UCP-2, UCP-3) gene expression. Endocrinology 1998, 139: 4920-7.
46. Hahn, S.E., Goldberg, D.M. Modulation of lipoprotein production in Hep G2 cells by fenofibrate and clofibrate. Biochem Pharmacol 1992, 43: 625-33.
47. Kesaniemi, Y.A., Grundy, S.M. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man. JAMA 1984, 251: 2241-6.
48. Desager, J.P., Horsmans, Y., Vandenplas, C., Harvengt, C. Pharmacodynamic activity of lipoprotein lipase and hepatic lipase and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days. Atherosclerosis 1996, 124 (Suppl.): S65-S73.
49. Foger, B., Drexel, H., Hopferwieser, T. Fenofibrate improves postprandial chylomicron clearance in II B hyperlipoproteinemia. Clin Investig 1994, 72: 294-301.
50. Quarfordt, S.H., Michalopoulos, G., Schirmer, B. The effect of human C apolipoproteins on the in vitro hepatic metabolism of triglyceride emulsions in the rat. J Biol Chem 1982, 257: 14642-7.
51. Windler, E., Chao, Y., Havel, R.J. Regulation of the hepatic uptake of triglyceride-rich lipoproteins in the rat. Opposing effects of homologous apolipoprotein E and individual C apoproteins. J Biol Chem 1980, 255: 8303-7.
52. Clavey, V., Lestavel-Delattre, S., Copin, C., Bard, J.M., Fruchart, J.C. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler Thromb Vasc Biol 1995, 15: 963-71.
53. Aalto-Setala, K., Fisher, E.A., Chen, X. et al. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest 1992, 90: 1889-900.
54. Aalto-Setala, K., Weinstock, P.H., Bisgaier, C.L., Wu, L., Smith, J.D., Breslow, J.L. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice. J Lipid Res 1996, 37: 1802-11.
55. Ebara, T., Ramakrishnan, R., Steiner, G., Shachter, N.S. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. J Clin Invest 1997, 99: 2672-81.
56. Maeda, N., Li, H., Lee, D., Oliver, P., Quarfordt, S.H., Osada, J. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J Biol Chem 1994, 269: 23610-6.
57. Li, W.W., Dammerman, M.M., Smith, J.D., Metzger, S., Breslow, J.L., Left, T. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest 1995, 96: 2601-5.
58. Malmendier, C.L., Lontie, J.F., Delcroix, C., Dubois, D.Y., Magot, T., De Roy, L. Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients. Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration. Atherosclerosis 1989, 77: 139-49.
59. Ginsberg, H.N., Le, N.A., Goldberg, I.J. et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 1986, 78: 1287-95.
60. Bard, J.M., Parra, H.J., Camare, R. et al. A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition. Metabolism 1992, 41: 498-503.
61. Haubenwallner, S., Essenburg, A.D., Barnett, B.C. et al. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: A potential physiologic basis for their mode of action. J Lipid Res 1995, 36: 2541-51.
62. Peters, J.M., Hennuyer, N., Staels, B. et al. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor α-deficient mice. J Biol Chem 1997, 272: 27307-12.
63. Ladias, J.A., Hadzopoulou-Cladaras, M., Kardassis, D. et al. Transcriptional regulation of human apolipoprotein genes ApoB, ApoCIII, and ApoAII by members of the steroid hormone receptor superfamily HNF-4, ARP-1, EAR-2, and EAR-3. J Biol Chem 1992, 267: 15849-60.
64. Vu-DaC, N., Gervois, P., Pineda Torra, I.P. et al. Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids. J Clin Invest 1998, 102: 625-32.
65. Hertz, R., Bishara-Shieban, J., Bar-Tana, J. Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III. J Biol Chem 1995, 270: 13470-5.
66. Hertz, R., Sheena, V., Kalderon, B., Berman, I., Bar-Tana, J. Suppression of hepatocyte nuclear factor-4α by acyl-CoA thioesters of hypolipidemic peroxisome proliferators. Biochem Pharmacol 2001, 61: 1057-62.
67. Vu-Dac, N., Chopin-Delannoy, S., Gervois, P. et al. The nuclear receptors peroxisome proliferator-activated receptor α and Rev-erbα mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J Biol Chem 1998, 273: 25713-20.
68. Gervois, P., Chopin-Delannoy, S., Fadel, A. et al. Fibrates increase human Rev-erbα expression in liver via a novel PPAR response element. Mol Pharmacol 1999, 13: 400-9.
69. Duez, H., Mansen, A., Fruchart, J.C., Vennstrom, B., Fievet, C., Staels, B. Rev-erbα: A nuclear receptor with a role in lipoprotein metabolism. Circulation 1998, 98, 17: I-449-2363.
70. Sakai, M., Matsushima-Hibiya, Y., Nishizawa, M., Nishi, S. Suppression of rat glutathione transferase P expression by peroxisome proliferators: Interaction between Jun and peroxisome proliferator-activated receptor α. Cancer Res 1995, 55: 5370-6.
71. Poynter, M.E., Daynes, R.A. Peroxisome proliferator-activated receptor α activation modulates cellular redox status, represses nuclear factor-κB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 1998, 273: 32833-41.
72. Staels, B., Koenig, W., Habib, A. et al. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature 1998, 393: 790-3.
73. Zhou, Y.C., Waxman, D.J. Cross-talk between janus kinase-signal transducer and activator of transcription (JAK-STAT) and peroxisome proliferator-activated receptor-α (PPARα) signaling pathways. Growth hormone inhibition of PPARα transcriptional activity mediated by STAT5b. J Biol Chem 1999, 274: 2672-81.
74. Pennacchio, L.A., Olivier, M., Hubacek, J.A. et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 2001, 294: 169-73.
75. Pennacchio, L.A., Olivier, M., Hubacek, J.A., Krauss, P.M., Rubin, E.M., Cohen, J.C. Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum Mol Genet 2002, 11: 3031-8.
76. Nabika, T., Nasreen, S., Kobayashi, S., Masuda, J. The genetic effect of the apoprotein AV gene on the serum triglyceride level in Japanese. Atherosclerosis 2002, 165: 201-4.
77. Fielding, C.J., Fielding, P.E. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995, 36: 211-28.
78. Reichl, D. Lipoproteins of human peripheral lymph. Eur Heart J 1990, 11(Suppl. E): 230-6.
79. Osono, Y., Woollett, L.A., Marotti, K.R., Melchior, G.W., Dietschy, J.M. Centripetal cholesterol flux from extrahepatic organs to the liver is independent of the concentration of high density lipoprotein-cholesterol in plasma. Proc Natl Acad Sci USA 1996, 93: 4114-9.
80. Jolley, C.D., Woollett, L.A., Turley, S.D., Dietschy, J.M. Centripetal cholesterol flux to the liver is dictated by events in the peripheral organs and not by the plasma high density lipoprotein or apolipoprotein A-I concentration. J Lipid Res 1998, 39: 2143-9.
81. Castro, G.R., Fielding, C.J. Early incorporation of cell-derived cholesterol into pre-β-migrating high-density lipoprotein. Biochemistry 1988, 27: 25-9.
82. Kawano, M., Miida, T., Fielding, C.J., Fielding, P.E. Quantitation of pre β-HDL-dependent and nonspecific components of the total efflux of cellular cholesterol and phospholipid. Biochemistry 1993, 32: 5025-8.
83. Huang, Y., von Eckardstein, A., Assmann, G. Cell-derived unesterified cholesterol cycles between different HDLs and LDL for its effective esterification in plasma. Arterioscler Thromb 1993, 13: 445-58.
84. Asztalos, B.F., Sloop, C.H., Wong, L., Roheim, P.S. Two-dimensional electrophoresis of plasma lipoproteins: Recognition of new apo A-I-containing subpopulations. Biochim Biophys Acta 1993, 1169: 291-300.
85. SS.Asztalos, B.F., Roheim, P.S. Presence and formation of 'free apolipoprotein A-I-like' particles in human plasma. Arterioscler Thromb Vasc Biol 1995, 15: 1419-23.
86. Asztalos, B., Zhang, W., Roheim, P.S., Wong, L. Role of free apolipoprotein A-I in cholesterol efflux. Formation of pre-α-migrating high-density lipoprotein particles. Arterioscler Thromb Vasc Biol 1997, 17: 1630-6.
87. Berthou, L., Duverger, N., Emmanuel, F. et al. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J Clin Invest 1996, 97: 2408-16.
88. Duez, H., Lefebvre, B., Poulain, P. et al. Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation. Arterioscler Thromb Vasc Biol 2005, 25: 585-91.
89. Hennuyer, N., Poulain, P., Madsen, L. et al. Beneficial effects of fibrates on apolipoprotein A-I metabolism occur independently of any peroxisome proliferative response. Circulation 1999, 99: 2445-51.
90. Duez, H., Chao, Y.S., Hernandez, M. et al. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor α agonist fenofibrate in mice. J Biol Chem 2002, 277: 48051-7.
91. Santamarina-Fojo, S., Remaley, AT., Neufeld, E.B., Brewer, N.B. Jr. Regulation and intracellular trafficking of the ABCA1 transporter. J Lipid Res 2001, 42: 1339-45.
92. Chinetti, G., Lestavel, S., Bocher, V. et al. PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001, 7: 53-8.
93. Kok, T., Bloks, V.W., Wolters, H. et al. Peroxisome proliferator- activated receptor α (PPARα)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. Biochem J 2003, 369: 539-47.
94. Kok, T., Wolters, H., Bloks, V.W. et al. Induction of hepatic ABC transporter expression is part of the PPARα-mediated fasting response in the mouse. Gastroenterology 2003, 124: 160-71.
95. Basso, F., Freeman, L., Knapper, C.L. et al. Role of the hepatic ABCA1 transporter in modulating intrahepatic cholesterol and plasma HDL cholesterol concentrations. J Lipid Res 2003, 44: 296-302.
96. Brewer, H.B., Santamarina-Fojo, S. New insights into the role of the adenosine triphosphate-binding cassette transporters in high-density lipoprotein metabolism and reverse cholesterol transport. Am J Cardiol 2003, 91: 3-11.
97. Forcheron, F., Cachefo, A., Thevenon, S., Pinteur, C., Beylot, M. Mechanisms of the triglyceride-and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients. Diabetes 2002, 51: 3486-91.
98. Chinetti, G., Lestavel, S., Fruchart, J.C., Clavey, V., Staels, B. Peroxisome proliferator-activated receptor α reduces cholesterol esterification in macrophages. Circ Res 2003, 92: 212-7.
99. Ji, Y., Jian, B., Wang, N. et al. Scavenger re-ceptor Bl promotes high density lipoprotein-mediated cellular cholesterol efflux. J Biol Chem 1997, 272: 20982-5.
100. Chinetti, G., Gbaguidi, F.G., Griglio, S. et al. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 2000, 101: 2411-7.
101. Heller, F.R., Desager, J.P., Harvengt, C. Plasma lipid concentrations and lecithin:cholesterol acyltransferase activity in normolipidemic subjects given fenofibrate and colestipol. Metabolism 1981, 30: 67-71.
102. Heller, F.R., Desager, J.P., Harvengt, C. Changes in plasma activities of lipolytic enzymes and lipids of normolipidemic subjects given phenobarbital, a strong microsomal inducer, alone or in combination with fenofibrate. Int J Clin Pharmacol Ther Toxicol 1988, 26: 138-42.
103. Hitz, J., Steinmetz, J., Siest, G. Plasma lecithin: cholesterol acyltransferase - reference values and effects of xenobiotics. Clin Chim Acta 1983, 133: 85-96.
104. Staels, B., Van Tol, A., Skretting, G., Auwerx, J. Lecithin:cholesterol acyltransferase gene expression is regulated in a tissue-selective manner by fibrates. J Lipid Res 1992, 33: 727-35.
105. Bouly, M., Masson, D., Gross, B. et al. Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate. J Biol Chem 2001, 276: 25841-7.
106. Marotti, K.R., Castle, C.K., Boyle, T.P., Lin, A.M., Murray, R.W., Melchior, G.W. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 1993, 364: 73-5.
107. Foger, B., Chase, M., Amar, M.J. et al. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J Biol Chem 1999, 274: 36912-20.
108. Hirano, K., Yamashita, S., Kuga, Y. et al. Atherosclerotic disease in marked hyper-α-lipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. Arterioscler Thromb Vasc Biol 1995, 15: 1849-56.
109. Ordovas, J.M., Cupples, L.A., Corella, D. et al. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. Arterioscler Thromb Vasc Biol 2000, 20: 1323-9.
110. Agerholm-Larsen, B., Tybjaerg-Hansen, A., Schnohr, P., Steffensen, R., Nordestgaard, B.G. Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol, and possible decreased risk of ischemic heart disease: The Copenhagen City Heart Study. Circulation 2000, 102: 2197-203.
111. Tu, A.Y., Albers, J.J. Functional analysis of the transcriptional activity of the mouse phospholipid transfer protein gene. Biochem Biophys Res Commun 2001, 287: 921-6.
112. Tu, A.Y., Albers, J.J. DNA sequences responsible for reduced promoter activity of human phospholipid transfer protein by fibrate. Biochem Biophys Res Commun 1999, 264: 802-7.
113. Liang, H.Q., Rye, K.A., Barter, P.J. Dissociation of lipid-free apolipoprotein A-I from high density lipoproteins. J Lipid Res 1994, 35: 1187-99.
114. Liang, H.Q., Rye, K.A., Barter, P.J. Cycling of apolipoprotein A-I between lipid-associated and lipid-free pools. Biochim Biophys Acta 1995, 1257: 31-7.
115. Mezdour, H., Jones, R., Dengremont, C., Castro, G., Maeda, N. Hepatic lipase deficiency increases plasma cholesterol but reduces susceptibility to atherosclerosis in apolipoprotein E-deficient mice. J Biol Chem 1997, 272: 13570-5.
116. Busch, S.J., Barnhart, R.L., Martin, G.A. et al. Human hepatic triglyceride lipase expression reduces high density lipoprotein and aortic cholesterol in cholesterol-fed transgenic mice. J Biol Chem 1994, 269: 16376-82.
117. Connelly, P.W., Hegele, R.A. Hepatic lipase deficiency. Crit Rev Clin Lab Sci 1998, 35: 547-72.
118. Sich, D., Saidi, Y., Giral, P. et al. Hyper-α-lipoproteinemia: Characterization of a cardioprotective profile associating increased high-density lipoprotein-2 levels and decreased hepatic lipase activity. Metabolism 1998, 47: 965-73.
119. Heller, F., Harvengt, C. Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects. Eur J Clin Pharmacol 1983, 25: 57-63.
120. Fidge, N.H. High density lipoprotein receptors, binding proteins, and ligands. J Lipid Res 1999, 40: 187-201.
121. Acton, S., Rigotti, A., Landschulz, K.T., Xu, S., Hobbs, H.H., Krieger, M. Identification of sea-venger receptor SR-BI as a high density lipoprotein receptor. Science 1996, 271: 518-20.
122. Hammad, S.M., Stefansson, S., Twal, W.O. et al. Cubilin, the endocytic receptor for intrinsic factor-vitamin B(12) complex, mediates high-density lipoprotein holoparticle endocytosis. Proc Natl Acad Sci USA 1999, 96: 10158-63.
123. Hammad, S.M., Barth, J.L., Knaak, C., Argraves, W.S. Megalin acts in concert with cubilin to mediate endocytosis of high density lipoproteins. J Biol Chem 2000, 275: 12003-8.
124. Kozyraki, R., Fyfe, J., Kristiansen, M. et al. The intrinsic factor-vitamin B12 receptor, cubilin, is a high-affinity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein. Nat Med 1999, 5: 656-61.
125. Christensen, E.I., Birn, H. Megalin and cubilin: Synergistic endocytic receptors in renal proximal tubule. Am J Physiol Renal Physiol 2001, 280: F562-F573.
126. Rigotti, A., Trigatti, B.L., Penman, M., Rayburn, H., Herz, J., Krieger, M. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc Natl Acad Sci USA 1997, 94: 12610-5.
127. Varban, M.L., Rinninger, F., Wang, N. et al. Targeted mutation reveals a central role for SR-BI in hepatic selective uptake of high density lipoprotein cholesterol. Proc Natl Acad Sci USA 1998, 95: 4619-24.
128. Kozarsky, K.F., Donahee, M.H., Glick, J.M., Krieger, M., Rader, D.J. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arterioscler Thromb Vasc Biol 2000, 20: 721-7.
129. Kozarsky, K.F., Donahee, M.H., Rigotti, A., Iqbal, S.N., Edelman, E.R., Krieger, M. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature 1997, 387: 414-7.
130. Ueda, Y., Gong, E., Royer, L., Cooper, P.N., Francone, O.L., Rubin, E.M. Relationship between expression levels and atherogenesis in scavenger receptor class B, type I transgenics. J Biol Chem 2000, 275: 20368-73.
131. Mardones, P., Pilon, A., Bouly, M. et al. Fibrates down-regulate hepatic scavenger receptor class B type I protein expression in mice. J Biol Chem 2003, 278: 7884-90.
132. Willnow, T.E., Hilpert, J., Armstrong, S.A. et al. Defective forebrain development in mice lacking gp330/megalin. Proc Natl Acad Sci USA 1996, 93: 8460-4.
133. Post, S.M., Duez, H., Gervois, P.P., Staels, B., Kuipers, F., Princen, H.M. Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-α-mediated downregulation of cholesterol 7α-hydroxylase and sterol 27-hydroxylase expression. Arterioscler Thromb Vasc Biol 2001, 21: 1840-5.
134. von Bergmann, K., Leiss, O. Effect of short-term treatment with bezafibrate and fenofibrate on biliary lipid metabolism in patients with hyperlipoproteinaemia. Eur J Clin Invest 1984, 14: 150-4.
135. Leiss, O., Meyer-Krahmer, K., von Bergmann, K. Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. Influence of bezafibrate and fenofibrate. J Lipid Res 1986, 27: 213-23.
136. Podda, M., Zuin, M. Effects of fenofibrate on biliary lipids and bile acid pool size in patients with type IV hyperlipoproteinemia. Atherosclerosis 1985, 55: 135-42.